EMEA-002945-PIP03-23 - paediatric investigation plan
frexalimab
PIPHuman
Key facts
- Active Substance
- frexalimab
- Therapeutic area
- Endocrine disorders
- Decision number
- P/0047/2024
- PIP number
- EMEA-002945-PIP03-23
- Pharmaceutical form(s)
- Solution for injection/infusion
- Condition(s) / indication(s)
- Treatment of type 1 diabetes mellitus
- Route(s) of administration
- Subcutaneous use
- Contact for public enquiries
Sanofi Winthrop Industrie
Email: contact-us@sanofi.com
Tel: +31 202 453 703- Decision type
- P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
- Decision date